Search Results 1 – 20 of 3231
Efavirenz / Lamivudine / Tenofovir Disoproxil Fumarate
https://clinicalinfo.hiv.gov/drugs/efavirenz-lamivudine-tenofovir-disoproxil-fumarate/fda-label
Page 404
https://clinicalinfo.hiv.gov/page-404
Página 404
https://clinicalinfo.hiv.gov/page-404
Guidelines Archive
https://clinicalinfo.hiv.gov/guidelines-archive
Table 20. Common and/or Severe Adverse Effects Associated with Antiretroviral Medications
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/adverse-effects-antiretroviral-medications-full
Appendix A, Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-characteristics-tables-nrti-full
Table 18. Concomitant Use of Selected Antiretroviral Drugs and Hepatitis C Virus Direct-Acting Antiviral Drugs for Treatment of Hepatitis C Virus in Adults With HIV
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/coinfections-hepatitis-c-virus-hiv-full
Appendix A, Table 5. Characteristics of Protease Inhibitors
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-characteristics-tables-pi-full
Table 2. Treatment of HIV-Associated Opportunistic Infections (Includes Recommendations for Acute Treatment and Secondary Prophylaxis/Chronic Suppressive/Maintenance Therapy)
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/treatment-hiv-associated-full
Potential Clinically Relevant Interactions between Antimalarial and Antiretroviral Drugs*
https://clinicalinfo.hiv.gov/table/potential-clinically-relevant-interactions-between-antimalarial-and-antiretroviral-drugs
Dosing Recommendations for Prevention and Treatment of Malaria
https://clinicalinfo.hiv.gov/table/dosing-recommendations-prevention-and-treatment-malaria
Table 1. Primary Prophylaxis of Opportunistic Infections in Children With and Exposed to HIV— Summary of Recommendations
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/table/table-1-primary-prophylaxis-full
Table 2. Secondary Prophylaxis of Opportunistic Infections in Children With and Exposed to HIV — Summary of Recommendations
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/table-2-secondary-prophylaxis-full
Table 3. Treatment of Opportunistic Infections in Children With and Exposed to HIV — Summary of Recommendations
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/table-3-treatment-full
Table 4. Common Drugs Used for Treatment of Opportunistic Infections in Children With HIV: Preparations and Major Toxicities
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/table/table-4-common-drugs-used-treatment-opportunistic-infections-hiv-infected-children
Table 5. HIV-Related Laboratory Monitoring Schedule During Pregnancy
https://clinicalinfo.hiv.gov/guidelines/perinatal/antepartum-care-initial-evaluation-monitoring-hiv-assessments-during-pregnancy-full
Table 14. Antiretroviral Drug Use in Pregnancy: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy
https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-drug-use-pregnant-full
Supplemental Table 1. Results of Major Studies on Antiretroviral Interventions to Prevent Perinatal HIV Transmission
https://clinicalinfo.hiv.gov/guidelines/perinatal/review-clinical-trials-arv-interventions-prevent-hiv-transmission-full
Appendix C. Clinical Trial Efficacy Data for Daily, Oral Tenofovir Disoproxil Fumarate/Emtricitabine as Pre-Exposure Prophylaxis
https://clinicalinfo.hiv.gov/table/appendix-c-clinical-trial-efficacy-data-daily-oral-tenofovir-disoproxil-fumarateemtricitabine
Raltegravir
https://clinicalinfo.hiv.gov/table/raltegravir